Innovent Biologics' IBI363 Shows Promising Results for Lung Cancer Treatment with Long-Term Survival Data

Innovent Biologics Unveils Promising Results at ASCO 2026

In a major presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Innovent Biologics, Inc. shared groundbreaking results from their clinical trial on IBI363, a PD-1/IL-2α biased bispecific fusion protein. Targeting patients with advanced non-small cell lung cancer (NSCLC) who are resistant to immunotherapy, IBI363 offers a new beacon of hope for those with limited treatment options.

Latest Clinical Findings

The recent data showcased during the ASCO meeting highlights the promising efficacy and safety outcomes stemming from a Phase 1 proof-of-concept (PoC) study of IBI363. Following an extended follow-up period, the results demonstrated a manageable long-term safety profile alongside significant improvements in overall survival rates among patients suffering from IO-resistant NSCLC.

The study included a total of 136 subjects, with results indicating a median overall survival (OS) of 18.2 months for patients with squamous NSCLC receiving the optimal 3 mg/kg dosing strategy, surpassing historical controls significantly. The survival rate at two years post-treatment was rated at an impressive 47.8% for squamous NSCLC, providing compelling evidence of IBI363’s long-term benefits compared to traditional therapies.

Addressing AdenoNSCLC

Notably, the findings also addressed the treatment of wild-type adenocarcinoma NSCLC patients. For this group, IBI363 demonstrated a median OS of 15.2 months, along with a 24-month survival rate of 42.7%. A particularly striking observation was that patients with a history of smoking had even longer survival benefits, reporting a median OS of 23.4 months across all dose groups. Such results underline the potential of IBI363, showcasing its unique efficacy in tackling this challenging cancer subtype.

Focus on Safety

While efficacy details are impressive, safety remains a crucial topic in cancer treatments. The long-term follow-up reported treatment-emergent adverse events (TEAEs) of grade 3 or above in 48.5% of participants, suggesting a relatively favorable safety profile. Common adverse effects, including arthralgia, anemia, and rash, were largely manageable, affirming the overall balance of therapeutic benefit versus risk.

Dr. Hui Zhou, Chief R&D Officer for Innovent's Oncology Pipeline, spoke enthusiastically about the trial’s outcomes. He emphasized that for lung cancer patients, especially those who do not carry driver gene mutations and have failed other therapies, these results signal a significant step forward. "These outstanding survival outcomes highlight the novel mechanisms of IBI363 and support the hope it offers for improved long-term survival in a patient population with previously few options," he stated.

Future Directions

Encouraged by these results, Innovent Biologics has announced plans for a global Phase 3 clinical trial, MarsLight-11, focusing on IO-resistant squamous NSCLC. Further regulatory communications are anticipated, paving the way for an expansive Phase 3 study of IBI363 for non-squamous NSCLC.

In addition to its innovative mechanism of dual immune checkpoint blockade combined with cytokine action that may drive the observed long-lasting efficacy, IBI363 has garnered Fast Track and Breakthrough Therapy Designations from both the U.S. FDA and China's NMPA. These classifications not only signify a faster regulatory review but also highlight the urgency behind finding effective treatments for patients battling advanced NSCLC.

Conclusion

With its remarkable safety profile and promising efficacy demonstrated through extensive clinical data, Innovent Biologics’ IBI363 emerges as a crucial player in the fight against advanced lung cancer. As the oncology community eagerly anticipates further findings, IBI363 stands to reshape treatment paradigms for patients who have otherwise faced disheartening prognoses. The ongoing commitment of Innovent to foster development in biopharmaceuticals remains emblematic of the company's mission to enhance patient outcomes in oncology and beyond.